SCLERODERMA, SYSTEMIC

This study tested whether tofacitinib, a drug that calms the immune system, works better than methotrexate at reducing skin hardening in people with a severe form of scleroderma. 34 adults with early-stage diffuse scleroderma took part. Researchers measured skin thickness using a…

This study tested whether imatinib (Glivec), a drug used for certain cancers, can reduce severe skin hardening in people with scleroderma. 28 adults with advanced skin involvement received either imatinib or a placebo for 6 months. The main goal was to measure changes in skin thi…

This study tested a new medicine called Avenciguat (BI 685509) in 214 adults with scleroderma, especially those with lung fibrosis or blood vessel issues. Participants took either the medicine or a placebo three times daily for at least 11 months. The main goal was to see if the …

This study looked at how certain immune cells (T cells and NK cells) might harm blood vessels in people with systemic sclerosis (scleroderma). Researchers took blood samples from 30 participants to measure a protein called Fractalkine and study cell interactions. The goal was to …

This study looked at whether certain immune cells (B lymphocytes) contribute to scarring in people with systemic sclerosis, a disease that causes skin and organ hardening. Researchers compared blood and skin samples from 71 participants—patients and healthy volunteers—to measure …

This study looked at 30 people with scleroderma, an autoimmune disease that often affects the hands. Researchers measured how much each hand could move and compared the dominant hand to the other. The goal was to better understand hand disability and guide future therapy.